Targeted Therapies in Oncology
September I, 2024
Volume: 13
Issue: 11
August I, 2024
Volume: 13
Issue: 10
July I, 2024
Volume: 13
Issue: 9
June 02, 2024
Volume: 13
Issue: 8
June I, 2024
Volume: 13
Issue: 7
May I, 2024
Volume: 13
Issue: 6
April I, 2024
Volume: 13
Issue: 5
March II, 2024
Volume: 13
Issue: 4
March I, 2024
Volume: 13
Issue: 3
February I, 2024
Volume: 13
Issue: 2
January I, 2024
Volume: 13
Issue: 1
December II, 2023
Volume: 12
Issue: 18
December I, 2023
Volume: 12
Issue: 17
November II, 2023
Volume: 12
Issue: 16
November I, 2023
Volume: 12
Issue: 15
October II, 2023
Volume: 12
Issue: 14
October I
Volume: 12
Issue: 13
September I
Volume: 12
Issue: 12
August I
Volume: 12
Issue: 11
July 1, 2023
Volume: 12
Issue: 9
July II, 2023
Volume: 12
Issue: 10
June 2023
Volume: 12
Issue: 8
May 2023
Volume: 12
Issue: 7
April 2, 2023
Volume: 12
Issue: 6
April 1, 2023
Volume: 12
Issue: 5
March 1, 2023
Volume: 12
Issue: 3
February 2023
Volume: 12
Issue: 2
January 2023
Volume: 11
Issue: 17
December 2, 2022
Volume: 11
Issue: 18
December 1, 2022
Volume: 11
Issue: 17
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
2
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
3
NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC
4
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
5